Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.
Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.
Smith
Kenneth J
KJ
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. kjs8@pitt.edu
Lee
Bruce Y
BY
Nowalk
Mary Patricia
MP
Raymund
Mahlon
M
Zimmerman
Richard K
RK
D002487:Centers for Disease Control and Prevention, U.S.; D003362:Cost-Benefit Analysis; D006801:Humans; D007252:Influenza Vaccines / Q000191:economics*; D007251:Influenza, Human / Q000517:prevention & control*; D008390:Markov Chains; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics*; D019057:Quality-Adjusted Life Years; D014481:United States; D014611:Vaccination / Q000191:economics*
D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines